Cassiopea is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. Our initial focus is on the topical treatment of acne; androgenic alopecia, or AGA; and genital warts. Our portfolio comprises four unencumbered clinical candidates, for which we own the worldwide rights. These product candidates are based on three new chemical entities, or NCEs. They target unmet medical needs and significant market opportunities in the medical dermatology market. Our management team has extensive experience in product development and commercialization, having served in prominent roles at several leading pharmaceutical and medical dermatology companies. Our strategy is to leverage this expertise to establish Cassiopea as a pure-play, fully integrated company whose mission is to identify, develop and commercialize treatments for skin diseases.